Last updated: September 14, 2026
Pazopanib hydrochloride is an oral multi-targeted tyrosine kinase inhibitor marketed primarily as Votrient by Novartis. The drug generated approximately $1 billion in annual global sales at peak commercialization, supported by renal cell carcinoma and soft-tissue sarcoma indications. Its commercial position weakened after U.S. and international generic entry, patent expiry, competing immuno-oncology therapies, and price pressure in oncology procurement.
The principal market outcome is a transition from branded oncology revenue to a multi-supplier generic market. Pazopanib remains clinically relevant where oral VEGFR-directed therapy is selected, but its growth prospects are limited because the product lacks current market exclusivity and competes with newer targeted and immunotherapy regimens.
What is pazopanib hydrochloride and how does it work?
Pazopanib hydrochloride is the hydrochloride salt of pazopanib, an oral kinase inhibitor. It inhibits vascular endothelial growth factor receptors 1, 2 and 3, platelet-derived growth factor receptors alpha and beta, and c-KIT. The mechanism suppresses angiogenesis and tumor-cell signaling.
| Attribute |
Data |
| Active ingredient |
Pazopanib hydrochloride |
| Brand |
Votrient |
| Original developer |
GlaxoSmithKline |
| Current originator commercial owner |
Novartis |
| Dosage form |
Film-coated oral tablets |
| Common strength |
200 mg and 400 mg |
| Standard adult dose |
800 mg once daily, subject to dose modification |
| FDA approval |
October 19, 2009 |
| Initial indication |
Advanced renal cell carcinoma |
| Later indication |
Advanced soft-tissue sarcoma after prior chemotherapy |
| FDA regulatory pathway |
New Drug Application |
| Drug class |
Multi-targeted tyrosine kinase inhibitor |
The FDA approved Votrient for advanced renal cell carcinoma in 2009 and expanded the label to advanced soft-tissue sarcoma in 2012. The product is administered orally, which gives it a commercial advantage over intravenous therapies but also makes substitution by generic tablets relatively straightforward [1].
What FDA-approved indications does pazopanib have?
Pazopanib is FDA-approved for two main adult oncology uses:
- Advanced renal cell carcinoma.
- Advanced soft-tissue sarcoma in patients who previously received chemotherapy.
The renal cell carcinoma market is the larger commercial opportunity. Pazopanib competed against Pfizer’s Sutent, Bayer and Onyx’s Nexavar, and later-generation combinations such as pembrolizumab plus axitinib and nivolumab plus cabozantinib.
The soft-tissue sarcoma indication is smaller and more specialized. Pazopanib is used after prior chemotherapy, which limits the eligible population and reduces its contribution to total revenue.
How does pazopanib compare with competing renal cell carcinoma drugs?
| Drug |
Company |
Main mechanism |
Commercial position |
| Pazopanib |
Novartis |
VEGFR, PDGFR and c-KIT inhibitor |
Generic, mature oral TKI |
| Sunitinib |
Pfizer |
Multi-targeted TKI |
Generic, mature market |
| Axitinib |
Pfizer |
VEGFR inhibitor |
Generic; remains used in combinations |
| Cabozantinib |
Exelixis |
VEGFR, MET and AXL inhibitor |
Branded, stronger later-line position |
| Lenvatinib |
Eisai |
VEGFR, FGFR and other kinase inhibitor |
Branded, often used in combinations |
| Pembrolizumab plus axitinib |
Merck and Pfizer |
PD-1 antibody plus VEGFR TKI |
Major first-line competitor |
| Nivolumab plus cabozantinib |
Bristol Myers Squibb and Exelixis |
PD-1 antibody plus TKI |
Major first-line and later-line competitor |
Pazopanib’s principal clinical advantage is its established oral dosing and long treatment history. Its disadvantages include hepatotoxicity monitoring, drug interactions, hypertension, diarrhea, fatigue, and reduced use in treatment algorithms that favor immune checkpoint inhibitor combinations.
When did pazopanib lose market exclusivity?
Pazopanib lost practical U.S. market exclusivity after expiration of the principal Votrient patent estate and the subsequent launch of generic tablets. The key composition and product protection was associated with U.S. Patent No. 7,943,621 and related patent rights covering pazopanib and its pharmaceutical use.
The exact commercial erosion date varied by jurisdiction and generic manufacturer because generic approval, settlement terms, launch licenses, and local patent expiry did not occur simultaneously. In the United States, generic pazopanib approvals began appearing in the early 2020s, with broader competition developing after the principal patent period ended.
| Milestone |
Approximate timing |
| FDA approval of Votrient |
2009 |
| Soft-tissue sarcoma approval |
2012 |
| Abbreviated New Drug Application challenges |
Mid-to-late 2010s |
| Principal U.S. patent expiry period |
2023 range, including applicable extensions |
| Initial U.S. generic approvals and launches |
Early 2020s |
| Broad generic price competition |
2023 onward |
| Current status |
Mature generic market with no meaningful brand exclusivity |
The Orange Book should be used for the operative patent listing and expiry calculation because listed patents, pediatric extensions, and regulatory exclusivity can change the effective date for ANDA approval [2].
What patents protect Votrient and pazopanib hydrochloride?
The core Votrient estate included composition-of-matter, pharmaceutical-composition, treatment-method and formulation rights. The most economically important protection was the patent covering pazopanib and its pharmaceutical use.
| Patent category |
Commercial relevance |
| Composition of matter |
Protects pazopanib chemical entity and salt forms |
| Pharmaceutical composition |
Covers tablets and compositions containing pazopanib |
| Method of treatment |
Covers use in cancer, including renal cell carcinoma and sarcoma |
| Formulation |
Can address tablet stability, dissolution or excipient combinations |
| Manufacturing |
May cover synthetic intermediates, processes or crystallization |
Patent protection for pazopanib was more valuable before generic entry than after approval of competing products. Once an ANDA applicant demonstrated a non-infringing position or resolved patent litigation through settlement, formulation and method-of-use patents generally had less ability to prevent full market substitution than a valid composition patent.
What formulations are protected by pazopanib patents?
Votrient is an immediate-release film-coated tablet. The commercial product uses 200 mg and 400 mg strengths, allowing an 800 mg daily dose through two 400 mg tablets or four 200 mg tablets.
Formulation protection is commercially narrower than composition-of-matter protection. Generic companies can often obtain approval by using different excipients, coating systems, manufacturing parameters or tablet dimensions, provided the product meets bioequivalence and quality requirements. Formulation patents can still affect individual ANDA applicants, but they rarely preserve broad brand exclusivity after the active ingredient becomes available.
What is the Orange Book status of Votrient?
Votrient is an FDA-approved small-molecule drug listed in the Orange Book. It is not a biologic and therefore does not use the Biologics Price Competition and Innovation Act biosimilar pathway.
The relevant competitive pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Generic manufacturers generally rely on the Votrient reference product for bioequivalence and may certify against listed patents under Paragraph IV.
The commercially relevant regulatory facts are:
- Votrient is a small-molecule reference drug.
- Generic applicants file ANDAs rather than biosimilar applications.
- Orange Book patents may create approval timing restrictions.
- Method-of-use patents can be addressed through carve-outs or section viii statements.
- No current FDA new chemical entity exclusivity remains.
- The brand has no practical ability to prevent generic substitution through regulatory exclusivity.
Which companies challenged pazopanib patents under Paragraph IV?
Multiple generic manufacturers pursued pazopanib hydrochloride tablets through ANDA filings. Publicly identified generic participants have included major U.S. and international manufacturers such as Teva, Par Pharmaceutical, Dr. Reddy’s Laboratories, Lupin and other ANDA applicants.
The challenge structure typically involved:
- Paragraph IV certification that listed patents were invalid, unenforceable or not infringed.
- Patent litigation by the Votrient rights holder.
- Negotiation of settlement terms or an authorized launch date.
- FDA approval after statutory litigation stays and regulatory requirements were satisfied.
The first Paragraph IV filer may receive 180-day generic exclusivity under the Hatch-Waxman Act if the statutory conditions are met. That exclusivity can delay additional generic competition, although settlement terms and forfeiture rules can alter the timing.
What patent litigation affected Votrient?
Votrient patent litigation centered on ANDA filings for pazopanib tablets and the validity or infringement of patents covering the active ingredient, pharmaceutical composition and related uses. Litigation was brought by GlaxoSmithKline and later involved Novartis as the oncology business transitioned to Novartis ownership.
The main legal issue was whether generic pazopanib products could enter before expiration of the asserted patents. Settlements in this type of case often provide a licensed entry date before the full patent term, but the financial terms and launch restrictions may be confidential.
No broad, current injunction is generally associated with the mature U.S. pazopanib market. The commercial question has shifted from whether generics can enter to how many suppliers remain active and how quickly reimbursement discounts reduce net prices.
How strong is the pazopanib patent estate?
The historical patent estate was strong because it included protection around a commercially important oncology molecule with a long period before generic entry. Its present strength is weak from a revenue-protection perspective because the main patent term has expired or no longer prevents broad generic competition.
| Factor |
Assessment |
| Composition-of-matter protection |
Historically strong; no longer commercially controlling |
| Formulation patents |
Moderate historically; limited current market effect |
| Method-of-use patents |
Narrower and more vulnerable to label carve-outs |
| Regulatory exclusivity |
Expired |
| Biosimilar barrier |
Not applicable |
| Generic substitution risk |
High |
| Manufacturing barrier |
Moderate at launch; low-to-moderate in mature supply |
| Litigation leverage |
Limited after broad generic entry |
| Brand pricing power |
Low |
The remaining barriers are operational rather than legal. Pazopanib requires controlled manufacturing, analytical testing, stability data, and regulatory compliance, but it is an established oral small molecule rather than a complex biologic. The market does not have the manufacturing difficulty associated with monoclonal antibodies, cell therapies or sterile injectables.
What is the financial trajectory of pazopanib and Votrient?
Votrient reached approximately $1 billion in annual sales during its mature branded period. Novartis reported Votrient sales of roughly $1 billion annually in the years before significant generic erosion. Revenue then declined as generic competition expanded and physicians increasingly used immune checkpoint inhibitor combinations in renal cell carcinoma.
| Period |
Financial direction |
Primary drivers |
| 2009-2012 |
Rapid growth |
New renal cell carcinoma launch and sarcoma expansion |
| 2013-2016 |
Mature growth |
Established oral TKI use and global reimbursement |
| 2017-2019 |
Stable to modest decline |
Competition from newer TKIs and immunotherapies |
| 2020-2021 |
Approximately $1 billion-scale sales |
Residual brand demand and delayed generic erosion |
| 2022-2024 |
Material decline |
Generic entry, patent expiry and treatment-mix shift |
| Post-2024 |
Low-growth or declining brand market |
Generic substitution and price compression |
Novartis’s reported product sales provide the most reliable public measure of brand revenue. Company reporting has placed Votrient among the mature oncology products exposed to generic competition and portfolio aging [3][4].
Revenue erosion is likely to be sharper in the United States than in markets where generic registration, tendering or reimbursement substitution occurred earlier or where local patent rights differed. Net sales can decline faster than prescription volume because generic competition reduces price, rebates increase, and branded access contracts become less valuable.
What is the revenue exposure to generic pazopanib?
The revenue exposure is concentrated in:
- U.S. oncology prescriptions.
- European hospital and specialty-pharmacy channels.
- Renal cell carcinoma maintenance and later-line treatment.
- Soft-tissue sarcoma use where clinicians retain pazopanib after chemotherapy.
- Patients who need an oral VEGFR inhibitor but cannot access or tolerate combination immunotherapy.
The addressable market remains clinically meaningful, but the value pool has shifted from originator economics to high-volume, low-margin generic supply. Generic manufacturers can capture volume without matching the historical Votrient price, while payers gain leverage through therapeutic interchange and formulary competition.
What generic launch scenarios exist for pazopanib?
The market has three likely commercial scenarios.
Scenario 1: Broad generic substitution
Multiple approved manufacturers supply 200 mg and 400 mg tablets. Payers prefer generic pazopanib, branded Votrient loses preferred status, and originator revenue falls rapidly. This is the base-case scenario for a mature oral oncology product.
Scenario 2: Limited supplier market
A small number of manufacturers remain active because of pricing pressure, raw-material constraints or low expected margins. Prices decline more slowly, but supply disruption risk rises. Specialty pharmacies may retain the brand for certain patients.
Scenario 3: Authorized generic or brand-defense strategy
The originator or a partner supplies an authorized generic, allowing the rights holder to retain part of the market while reducing the economic benefit available to independent generic companies. This strategy can protect channel access but normally accelerates price erosion.
The most likely long-term structure is a multi-supplier market with low annual price growth, periodic shortages or discontinuations among low-volume suppliers, and limited ability for Votrient to regain premium pricing.
Does pazopanib face biosimilar competition?
No. Pazopanib is a chemically synthesized small molecule, not a biologic. Biosimilar competition does not apply.
Its competitors are generic tablets approved through ANDAs, branded oral kinase inhibitors, immune checkpoint inhibitors, and combination regimens. The absence of a biosimilar pathway does not reduce competitive risk; generic substitution is generally more direct for an oral small molecule.
What licensing deals affect pazopanib?
GlaxoSmithKline originally developed and commercialized pazopanib. Novartis acquired GSK’s oncology portfolio in 2015, including Votrient, as part of a larger asset exchange involving oncology and other pharmaceutical businesses [5].
The transaction changed the product’s commercial owner but did not extend the underlying patent term. Following the transfer, Votrient became part of Novartis’s established oncology portfolio alongside products such as Tasigna, Afinitor and Tafinlar/Mekinist.
Generic licensing arrangements, authorized-generic structures and Paragraph IV settlements may affect individual launch timing. Most detailed commercial terms are not publicly disclosed, so the central investment conclusion remains tied to the patent expiry and generic-approval record rather than to a disclosed licensing royalty stream.
How does pazopanib compare with other mature oncology products?
Pazopanib has a less defensible post-patent position than complex biologics because its dosage form is an oral immediate-release tablet and the active ingredient is chemically defined. It has a stronger established clinical base than many niche oral oncology drugs, but its brand value is constrained by generic substitution.
| Metric |
Pazopanib |
Mature biologic oncology drug |
| Regulatory competition |
ANDA generics |
Biosimilars and interchangeability rules |
| Manufacturing complexity |
Moderate |
High |
| Formulation substitution |
Relatively straightforward |
More difficult |
| Patent dependence |
High before expiry |
Often layered with device and formulation rights |
| Price erosion after entry |
Potentially rapid |
Often slower and staged |
| Current exclusivity |
None of commercial significance |
Product-specific |
Key Takeaways
- Pazopanib hydrochloride is the active ingredient in Votrient, Novartis’s oral multi-targeted tyrosine kinase inhibitor.
- FDA-approved uses are advanced renal cell carcinoma and advanced soft-tissue sarcoma after prior chemotherapy.
- Votrient reached approximately $1 billion in annual sales before generic erosion.
- The principal patent estate no longer provides effective broad U.S. market exclusivity.
- Generic competition is the main commercial force, not biosimilar competition.
- Renal cell carcinoma combination regimens have reduced pazopanib’s first-line growth opportunity.
- Formulation and method-of-use patents have less economic power than the expired composition protection.
- The post-exclusivity market is likely to have high generic substitution, lower prices and declining branded revenue.
- Manufacturing barriers are manageable for experienced generic suppliers.
- The product remains commercially relevant as a low-cost oral oncology therapy, especially in later-line renal cell carcinoma and soft-tissue sarcoma.
FAQs About Pazopanib Hydrochloride Patents and Market Economics
Is pazopanib hydrochloride still under patent?
The principal patent protection that supported Votrient’s U.S. exclusivity has expired or no longer prevents broad generic competition. Any remaining patent listings must be evaluated through the current FDA Orange Book.
What is the generic name for Votrient?
The generic name is pazopanib hydrochloride. Generic tablets are commonly approved in 200 mg and 400 mg strengths.
Is pazopanib cheaper than branded Votrient?
Generic pazopanib is generally priced below branded Votrient because multiple manufacturers compete for formulary and pharmacy distribution. Actual net pricing varies by country, payer and supplier.
Can pazopanib be substituted automatically for Votrient?
Substitution depends on state pharmacy law, payer policy, FDA product ratings and the specific generic product. Pharmacists and payers commonly treat approved generic pazopanib as therapeutically substitutable when permitted.
What is the long-term investment outlook for pazopanib?
The long-term outlook is mature to declining. Volume can persist because pazopanib remains clinically useful, but originator revenue growth is unlikely without a new formulation, indication, combination strategy or differentiated distribution arrangement.
References
- U.S. Food and Drug Administration. (2009). Votrient (pazopanib hydrochloride) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- Novartis AG. (2021). Annual report 2021. https://www.novartis.com/investors/financial-data/annual-report
- Novartis AG. (2023). Annual report 2023. https://www.novartis.com/investors/financial-data/annual-report
- Novartis AG. (2015). Novartis and GSK complete transaction to create focused leaders in pharmaceuticals and consumer healthcare. https://www.novartis.com/news/media-releases/novartis-and-gsk-complete-transaction-create-focused-leaders-pharmaceuticals-and-consumer-healthcare
